0001213900-20-023261.txt : 20200821 0001213900-20-023261.hdr.sgml : 20200821 20200821160732 ACCESSION NUMBER: 0001213900-20-023261 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200819 FILED AS OF DATE: 20200821 DATE AS OF CHANGE: 20200821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Liatos John CENTRAL INDEX KEY: 0001821508 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37823 FILM NUMBER: 201123487 MAIL ADDRESS: STREET 1: 12707 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kintara Therapeutics, Inc. CENTRAL INDEX KEY: 0001498382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990360497 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 350-4364 MAIL ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: DelMar Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130123 FORMER COMPANY: FORMER CONFORMED NAME: Berry Only Inc. DATE OF NAME CHANGE: 20100805 3 1 ownership.xml X0206 3 2020-08-19 1 0001498382 Kintara Therapeutics, Inc. KTRA 0001821508 Liatos John 12707 HIGH BLUFF DR. SUITE 200 SAN DIEGO CA 92130 1 1 0 0 SVP, Business Development On August 19, 2020, the merger (the "Merger") of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero Biopharmaceuticals Holdings, Inc., pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020, was completed. This report reflects the beneficial ownership of the Reporting Person at the time of completion of the Merger and does not include the securities of the Issuer acquired by the Reporting Person upon the completion of the Merger. The Reporting Person will file a Form 4 reflecting the Reporting Person's acquisition of securities of the Issuer in connection with the completion of the Merger. Exhibit List Exhibit 24 - Power of Attorney /s/ Anthony Scott Praill, attorney-in-fact for John Liatos 2020-08-21 EX-24 2 ea125836ex24_kintara.htm POWER OF ATTORNEY

Exhibit 24

POWER OF ATTORNEY

Known by all those present, that John Liatos hereby constitutes and appoints Scott Praill as his true and lawful attorney-in-fact with respect to DelMar Pharmaceuticals, Inc. to:

(1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 13 and 16(a) of the Securities Exchange Act of 1934, or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned Schedules 13D and 13G, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G, and Forms 3, 4, and 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney in fact’s discretion.

The undersigned hereby grants to attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s designated substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned’s responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of August, 2020.

	/s/ John Liatos
	Name:	John Liatos